← Back to patent-cliff list
Emilumenib succinate
Tier C — Watch / tradeEmilumenib succinate
Daiichi Sankyo Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Acute myeloid leukaemia, Lymphocytic leukaemia
Regional status
US
-
EU
-
China
-
Japan
Phase II
2021-04-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Emilumenib succinate?
Approved indications include: Acute myeloid leukaemia, Lymphocytic leukaemia.
When does the Emilumenib succinate patent expire?
No public expiry year is available for Emilumenib succinate yet; this page updates once verified.
How do I get a quote for Emilumenib succinate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06